LYMPHO-CLEAR: Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
Study Details
Study Description
Brief Summary
The purpose of this study is to determine the kinetics of circulating tumor DNA (ctDNA) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma (DLBCL). Modelizing the short-term kinetics of ctDNA would help to determine the optimal time-point for ctDNA follow-up. The investigators hypothesize that the greater ctDNA release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
ctDNA in diffuse large B cell lymphoma (DLBCL) has become an essential dynamic biomarker. Due to its short half-life, ctDNA is a real-time reflection of tumoral evolution and is a non-invasive biomarker that can be used for patient evaluation and follow-up. The quantity of ctDNA before treatment is correlated with tumoral mass, international prognostic index (IPI) and prognosis. The principal mechanism of ctDNA release is tumor cell apoptosis and it is well established that tumor cell apoptosis is observed in the hours following immuno-chemotherapy. However, the kinetics of ctDNA concentration in the hours following immuno-chemotherapy administration is unknown.
Modelizing the kinetics of ctDNA during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor, through release of a larger quantity of ctDNA compared to baseline.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Kinetics of circulating tumor DNA
|
Other: Measure of the circulating tumor DNA
Blood assessment to measure the kinetics au circulating tumor DNA
|
Outcome Measures
Primary Outcome Measures
- Analysis of circulating tumor DNA kinetics [21 days]
Blood assessment to measure circulating tumor concentration
Secondary Outcome Measures
- Correlation between circulating tumor DNA concentration and metabolic volume [6 months]
comparison between circulating tumoral concentration and metabolic volume measured on TEP
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years or older
-
Diffuse Large B Cell Lymphoma
-
TEP-TDM at diagnosis
-
Inform Consent form signed
-
Performance status 0 or 1
-
Hospitalized on clinician decision for first cycle of R-CHOP or R-miniCHOP
Exclusion Criteria:
-
Histology other than Diffuse Large B Cell
-
Patient under guardianship or curatorship
-
Incapacity to understand the study or conform to the constraints of the study (language barrier, psychological barrier, geographic barrier…)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Centre Henri Becquerel | Rouen | France | 76000 |
Sponsors and Collaborators
- Centre Henri Becquerel
Investigators
- Principal Investigator: Fabrice Jardin, MD,PhD, Centre Henri Becquerel
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHB23.05